![](https://endpts.com/wp-content/uploads/2023/03/Faheem-Hasnain-Gossamer-BIO22-feature.jpg)
Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)
Gossamer lays off 25% of employees, cuts all programs except PAH drug
As Gossamer Bio goes all in on its lead drug for pulmonary arterial hypertension (PAH), it’s cutting off all other clinical and preclinical programs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.